Oracle Completes Acquisition of Phase Forward
Oracle and Phase Forward executives offered their welcome as Phase Forward officially becomes part of the Oracle Health Sciences Global Business Unit.
The Webex conference for customers and partners this morning allowed Neil de Crescenzo, Senior Vice President and General Manager, Oracle Health Sciences, to provide Oracle's overarching strategy in regard to IT in all vertical markets. He then drilled down into its strategy for the Health Sciences unit, which is based on the ultimate convergence of life sciences and healthcare processes into translational and personalized medicine--and specifically using the efficiencies of data interoperability as necessary to achieve the goals.
From Phase Forward's perspective, both Steve Rosenberg, Senior Vice President, Products and Services, and Steve Powell, Senior Vice President Global Sales and Marketing, presented the benefits of the merger for customers. The main takeaway from Rosenberg for Phase Forward customers was that their "investment protected and their services intact."
In the new structure, customers will be able to take advantage of Oracle's Applications Unlimited, which offers customers basically whatever they choose moving forward..stay on the existing platform, upgrade or update to others, etc.
Powell reiterated that the merger was transformational in the industry and that by choosing Phase Forward, Oracle emphasizes the need of its applications within this industry, which will command a significant level of investment in the coming years.
Powell said that all upcoming Oracle and Phase Forward events this year are unaffected by the purchase. These events include Oracle's Open World, on September 19-23 in San Francisco, the Prix Galien on September 28 in New York City, Oracle Health Sciences User Group Annual Conference on October 10-13 in San Antonio, TX, and the Phase Forward International Users Conference in Orlando on October 26-28.
FDA Finalizes Decentralized Clinical Trial Guidance
November 25th 2024The FDA's guidance is part of a broader effort to modernize clinical trials, improve efficiency, reduce participant burden, and expand access, particularly for underrepresented populations and those in geographically or economically constrained areas.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Patient Engagement Platform Checklist
November 22nd 2024Modern clinical trials are more complex than ever, and one significant reason is the increased focus on patient engagement. Incorporating a patient engagement platform into your clinical trial enhances the patient experience and can lead to more successful trials with stronger, more reliable outcomes. We put together this helpful checklist of key features to look out for when choosing a platform for your study.
The Rise of Predictive Engagement Tools in Clinical Trials
November 22nd 2024Patient attrition can be a significant barrier to the success of a randomized controlled trial (RCT). Today, with the help of AI-powered predictive engagement tools, clinical study managers are finding ways to proactively reduce attrition rates in RCTs, and increase the effectiveness of their trial. In this guide, we look at the role AI-powered patient engagement tools play in clinical research, from the problems they’re being used to solve to the areas and indications in which they’re being deployed.
